Resources Repository
-
EditorialPublication 2020Waiting for Certainty on COVID-19 Antibody Tests — At What Cost?
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation …
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation policy to reduce COVID-19 transmission. For example: Could we screen for serologic antibodies as a proxy for possible immunity and identify people who could return to the workplace with less severe mitigation measures? The authors acknowledge the uncertainties raised by many policy actors, including the WHO, such as, "Do antibodies confer immunity and, if so, for how long? How accurate is…
Infectious Diseases | Technology Assessment | Probability/Bayes | Test Performance | Health Systems | Policy/Regulation | Government/Law | Health/Medicine | Global | North America -
ReviewPublication 2015Medicare's Use of CEA for Prevention (But Not Treatment)
Medicare currently pays for 23 preventive services in its benefits package, the majority of which …
Medicare currently pays for 23 preventive services in its benefits package, the majority of which were added since 2005. In the past decade, the program has transformed from one essentially administering treatment claims, to one increasingly focused on health promotion and maintenance. What is largely unappreciated is the role cost-effectiveness analysis has played in the coverage of preventive services. This study reviews the role of cost-effectiveness analysis in Medicare coverage of preventive services and contrast it…
Infectious Diseases | Technology Assessment | Priority Setting/Ethics | Cost-Effectiveness Analysis | Child/Nutrition | Chronic Disease/Risk | Health Systems | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine | North America -
ReviewPublication 2008Modeling Cervical Cancer Prevention in Developed Countries
Decision-analytic models are increasingly developed to simulate disease burden and interventions in different settings in …
Decision-analytic models are increasingly developed to simulate disease burden and interventions in different settings in order to evaluate the benefits and cost-effectiveness of primary and secondary interventions. This article is a review of mathematical models that have been used to evaluate HPV vaccination in the context of developed countries with existing screening programs. Despite variations in model assumptions and uncertainty in existing data, pre-adolescent vaccination of females in the setting of current screening practices has…
Calibration/Validation | Infectious Diseases | Mathematical Models | State-Transition | Dynamic Transmission | Microsimulation | Chronic Disease/Risk | Health/Medicine | Science/Technology